Schuemie M - Search Results

1

Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.

Yuan Z, DeFalco F, Wang L, Hester L, Weaver J, Swerdel JN, Freedman A, Ryan P, Schuemie M, Qiu R, Yee J, Meininger G, Berlin JA, Rosenthal N. Yuan Z, et al. Among authors: schuemie m. Curr Med Res Opin. 2020 Jul;36(7):1117-1124. doi: 10.1080/03007995.2020.1761312. Epub 2020 May 14. Curr Med Res Opin. 2020. PMID: 32338068

2

Evaluating the impact of database heterogeneity on observational study results.

Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, Suchard MA, DuMouchel W, Berlin JA. Madigan D, et al. Among authors: schuemie m. Am J Epidemiol. 2013 Aug 15;178(4):645-51. doi: 10.1093/aje/kwt010. Epub 2013 May 5. Am J Epidemiol. 2013. PMID: 23648805 Free PMC article.

3

Interpreting observational studies: why empirical calibration is needed to correct p-values.

Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Schuemie MJ, et al. Stat Med. 2014 Jan 30;33(2):209-18. doi: 10.1002/sim.5925. Epub 2013 Jul 30. Stat Med. 2014. PMID: 23900808 Free PMC article.

4

Discussion: An estimate of the science-wise false discovery rate and application to the top medical literature.

Schuemie MJ, Ryan PB, Suchard MA, Shahn Z, Madigan D. Schuemie MJ, et al. Biostatistics. 2014 Jan;15(1):36-9; discussion 39-45. doi: 10.1093/biostatistics/kxt037. Epub 2013 Sep 25. Biostatistics. 2014. PMID: 24068252 Free PMC article. No abstract available.

5

Desideratum for evidence based epidemiology.

Overhage JM, Ryan PB, Schuemie MJ, Stang PE. Overhage JM, et al. Drug Saf. 2013 Oct;36 Suppl 1:S5-14. doi: 10.1007/s40264-013-0102-2. Drug Saf. 2013. PMID: 24166219 Review.

6

Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey.

Stang PE, Ryan PB, Overhage JM, Schuemie MJ, Hartzema AG, Welebob E. Stang PE, et al. Drug Saf. 2013 Oct;36 Suppl 1:S15-25. doi: 10.1007/s40264-013-0103-1. Drug Saf. 2013. PMID: 24166220

7

Defining a reference set to support methodological research in drug safety.

Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Ryan PB, et al. Drug Saf. 2013 Oct;36 Suppl 1:S33-47. doi: 10.1007/s40264-013-0097-8. Drug Saf. 2013. PMID: 24166222 Review.

8

Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system.

Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Ryan PB, et al. Drug Saf. 2013 Oct;36 Suppl 1:S59-72. doi: 10.1007/s40264-013-0099-6. Drug Saf. 2013. PMID: 24166224

9

Empirical performance of the case-control method: lessons for developing a risk identification and analysis system.

Madigan D, Schuemie MJ, Ryan PB. Madigan D, et al. Drug Saf. 2013 Oct;36 Suppl 1:S73-82. doi: 10.1007/s40264-013-0105-z. Drug Saf. 2013. PMID: 24166225

10

Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system.

Ryan PB, Schuemie MJ, Madigan D. Ryan PB, et al. Drug Saf. 2013 Oct;36 Suppl 1:S95-106. doi: 10.1007/s40264-013-0101-3. Drug Saf. 2013. PMID: 24166227

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

194 results

Search Page